What is the recommended cefepime (2 g) and tazobactam (250 mg) dosing regimen for an adult with a lung infection and normal renal function?

Cefepime-Tazobactam Dosing for Adult Lung Infection

For adults with normal renal function and hospital-acquired or ventilator-associated pneumonia requiring antipseudomonal coverage, administer cefepime 2 g IV every 8 hours as a 30-minute to 3-hour infusion 1, 2. The tazobactam 250 mg dose you mentioned is not a standard formulation—the established combination is piperacillin-tazobactam, not cefepime-tazobactam in routine clinical practice.

Critical Clarification on Drug Combination

The combination "cefepime 2 g + tazobactam 250 mg" appears to reference WCK 4282 (cefepime-tazobactam), an investigational agent being developed for ESBL-producing organisms resistant to piperacillin-tazobactam 3. However, this is not yet FDA-approved and the standard tazobactam dose in this combination is 2 g, not 250 mg 3.

Standard Evidence-Based Dosing for Lung Infections

For Hospital-Acquired Pneumonia (HAP) or Ventilator-Associated Pneumonia (VAP):

Cefepime monotherapy (FDA-approved):

• 2 g IV every 8 hours for moderate to severe pneumonia 1, 2
• Infuse over 30 minutes (standard) or consider extended infusion over 1.5-4 hours for enhanced pharmacodynamics 3, 4
• Duration: 7-10 days typically 2

Pharmacodynamic Optimization:

The goal is achieving >60% fT>MIC (free drug time above MIC) to maximize microbiological response 5. For Pseudomonas aeruginosa specifically:

• Standard 2 g every 8 hours achieves this target for organisms with MIC ≤8 mg/L 5
• Extended infusions (3-4 hours) improve target attainment without increasing total daily dose 4, 6

Renal Function Adjustments:

Critical dosing modifications based on creatinine clearance (CrCL):

• CrCL >120 mL/min (augmented clearance): 2 g every 6 hours OR 2 g every 8 hours with 4-hour infusion 4
• CrCL 60-120 mL/min: 2 g every 8 hours (standard) 2
• CrCL 30-60 mL/min: 2 g every 12 hours 2
• CrCL 11-29 mL/min: 2 g every 24 hours 2
• CrCL <11 mL/min: 1 g every 24 hours 2
• Hemodialysis: 1 g on day 1, then 500 mg every 24 hours; give after dialysis 2

When to Use Combination Therapy

For VAP with risk factors for multidrug resistance, cefepime should be combined with a second antipseudomonal agent from a different class 1:

Risk factors requiring dual coverage:

• Prior IV antibiotics within 90 days
• Septic shock at VAP onset
• ARDS preceding VAP
• ≥5 days hospitalization before VAP
• Acute renal replacement therapy before VAP

Recommended combinations:

• Cefepime 2 g IV q8h PLUS one of:
  • Ciprofloxacin 400 mg IV q8h
  • Amikacin 15-20 mg/kg IV q24h
  • Gentamicin 5-7 mg/kg IV q24h

Common Pitfalls to Avoid

1. Neurotoxicity risk: Cefepime accumulation in renal impairment causes encephalopathy—always adjust for CrCL 6
2. Inadequate dosing in augmented clearance: Critically ill patients may have CrCL >120 mL/min requiring increased frequency 4
3. Confusing drug combinations: Piperacillin-tazobactam (4.5 g q6h) is different from cefepime monotherapy—don't mix formulations 1, 7
4. MRSA coverage: Cefepime has NO MRSA activity—add vancomycin 15 mg/kg q8-12h or linezolid 600 mg q12h if MRSA risk factors present 1

Investigational Cefepime-Tazobactam (If Referring to WCK 4282)

If you specifically mean the investigational combination:

• Dosing: Cefepime 2 g + tazobactam 2 g (not 250 mg) every 8 hours as 1.5-hour infusion 3
• Indication: ESBL-producing organisms resistant to piperacillin-tazobactam 3, 8
• Status: Not yet FDA-approved for routine use 3

The 250 mg tazobactam dose has no established clinical role—verify your intended regimen with pharmacy.